JAK1 inhibition and inflammatory bowel disease

C Harris, JRF Cummings - Rheumatology, 2021 - academic.oup.com
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …
被引用次数：42 相关文章

JAK1 inhibition and inflammatory bowel disease

C Harris, JRF Cummings - Rheumatology (Oxford …, 2021 - pubmed.ncbi.nlm.nih.gov
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …
[PDF] semanticscholar.org

[PDF][PDF] JAK1 inhibition and inflammatory bowel disease

C Harris, JRF Cummings - pdfs.semanticscholar.org
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

JAK1 inhibition and inflammatory bowel disease.

C Harris, JR Cummings - Rheumatology, 2021 - search.ebscohost.com
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …
[HTML] nih.gov

[HTML][HTML] JAK1 inhibition and inflammatory bowel disease

C Harris, JRF Cummings - Rheumatology (Oxford, England), 2021 - ncbi.nlm.nih.gov
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

JAK1 inhibition and inflammatory bowel disease.

C Harris, JRF Cummings - Rheumatology (Oxford, England), 2021 - europepmc.org
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

JAK1 inhibition and inflammatory bowel disease.

C Harris, JRF Cummings - Rheumatology (Oxford, England), 2021 - europepmc.org
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …